- Home
- NEA vs SNY Comparison
NEA vs SNY Comparison
Compare NEA & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEA
- SNY
- Stock Information
- Founded
- NEA 2002
- SNY 1994
- Country
- NEA United States
- SNY France
- Employees
- NEA N/A
- SNY N/A
- Industry
- NEA Finance/Investors Services
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- NEA Finance
- SNY Health Care
- Exchange
- NEA Nasdaq
- SNY Nasdaq
- Market Cap
- NEA 3.4B
- SNY 113.4B
- IPO Year
- NEA N/A
- SNY N/A
- Fundamental
- Price
- NEA $11.35
- SNY $46.61
- Analyst Decision
- NEA
- SNY Buy
- Analyst Count
- NEA 0
- SNY 4
- Target Price
- NEA N/A
- SNY $61.50
- AVG Volume (30 Days)
- NEA 803.4K
- SNY 2.8M
- Earning Date
- NEA 01-01-0001
- SNY 10-24-2025
- Dividend Yield
- NEA 4.23%
- SNY 3.43%
- EPS Growth
- NEA N/A
- SNY 118.56
- EPS
- NEA N/A
- SNY 8.65
- Revenue
- NEA N/A
- SNY $53,714,621,258.00
- Revenue This Year
- NEA N/A
- SNY $1.53
- Revenue Next Year
- NEA N/A
- SNY $7.06
- P/E Ratio
- NEA N/A
- SNY $5.39
- Revenue Growth
- NEA N/A
- SNY 15.65
- 52 Week Low
- NEA $9.20
- SNY $44.73
- 52 Week High
- NEA $11.37
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- NEA 66.73
- SNY 40.69
- Support Level
- NEA $10.92
- SNY $46.79
- Resistance Level
- NEA $11.46
- SNY $47.69
- Average True Range (ATR)
- NEA 0.07
- SNY 0.68
- MACD
- NEA 0.04
- SNY -0.26
- Stochastic Oscillator
- NEA 79.63
- SNY 27.40
About NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.